At the moment, the recommended treatment for COPD in Europe is an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA), or LABA/LAMA dual ...

Moreover, 15% of them were taking LAMA or LABA therapies in combination with inhaled corticosteroids ... company's lead drug candidate into the large COPD market in late 2023 or 2024.

The Spanish COPD guidelines recommend treatment ... a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'.

whereas group B must be given long-acting muscarinic antagonist (LAMA) or a LABA, and groups C and D should take an ICS in combination. In terms of stable COPD management, the most important ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...